Docetaxel induced pericardial effusion

Journal of Experimental and Clinical Cancer Research

Volumn 26, Issue 3, 2007, Pages 417-420

  Vincenzi, Bruno ^a   Santini, D ^a   Frezza, A M ^a   Rocci, L ^a   Tonini, G ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Docetaxel; Pericardial effusion

Indexed keywords

CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE;

ADULT; ARTICLE; CANCER GROWTH; CASE REPORT; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; CYTOLOGY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; PERICARDIAL EFFUSION; PERICARDIOCENTESIS; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PERICARDIAL EFFUSION; TAXOIDS;

EID: 35348895513     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Ganansia L.V., Bischoff P., Bergerat J.P. et al.: Signal trasduction pathways of taxanes induced apoptosis. Curr. Med. Chem. Anticanc. Agents. 3:291-306, 2003.
2. Shepherd S.A., Dancey J., Ramlau R., et al.: Prospective randomized trial of docetaxel versus best supportive care in patients with NSCLC previously treated with platinum based chemotherapy. J. Clin. Oncol. 18: 2095-2103, 2000.
3. Fossella F.V., De Vore R., Kerr R.N., et al.: Randomized Phase III trial of Docetaxel Versus Vinorelbine or Isofosfamide in patients with Advanced Non Small Cell Lung Cancer previously treated with platinum containing chemotherapy Regimens. J. Clin. Oncol. 18: 2354-2361, 2000.
4. Pfister D.G., Johnson D.H., Azzoli C.G. et a.l: American Society of Clinical Oncology treatment of unresectable NSCLC Guideline: update 2003. J. Clin. Oncol. 22: 330-352, 2003.
5. Scagliotti G.V., Turrisi A.I., et al.: Docetaxel -based combined- modality chemotherapy for locally advanced non small cell lung cancer. Oncologist. 8: 361-374, 2003.
6. Kastumasa K., Bando H, Saji S. et al.: Protracted administration of weekly docetaxel in metastatic breast cancer. Oncol. Report. 10: 1479-1484, 2003.
7. Hainswotrh J.D., Burrish A.I., Erland J.B. et al.: Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J. Clin. Oncol. 16: 2164-2168, 1998.
8. Burris H., Irvin R., Kuhn J., et al.: Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. J. Clin. Oncol.11: 950-958, 1993.
9. Fossella F.V., Lee J.S., Murphy W.K., et al.: Phase II study of docetaxel for recurrent or metastatic NSCLC J. Clin. Oncol. 12: 1238-1244, 1994.
10. Tomiak E., Piccart M.J., Kerger J. et al.: Phase I study of docetaxel administered as 1 hour intravenous infusion on a weekly basis. J. Clin. Oncol.12: 1458-1467, 1994.
11. Piccart M.J., Klijn J., Paridaens R. et al.: Corticosteroids significantly delay the onset of docetaxel-induced fluid retention. J Clin Oncol.15: 3149-3155, 1997.
12. Wachters F.M., van Putten J.W., Boezen H.M., Groen H.J.: Phase II study of docetaxel and carboplatin as second-line treatment in NSCLC. Lung Cancer. 45: 255-62, 2004.
13. Laak E., Dierlamm T., Knuffmann C., et al.: Docetaxel and carboplatin as second line chemotherapy for metastatic NSCLC. Lung Cancer. 36: 303-307, 2002.
14. Chevallier B., Fumoleau P., Kerbrat P., et al.: Docetaxel is a major citotoxic drug for the treatment of advanced breast cancer: a phase II trial of the clinical screening cooperative group of the European organization for research and treatment of cancer. J. Clin. Oncol. 13: 314-322, 2005.
15. Behrens R.J., Gulley J.L., Dahut W.L. et al.: Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide. Am. J. Therap. 10: 228-232, 2003.